Bronchodilator reversibility testing: Laboratory practices in Australia and New Zealand

Medical Journal of Australia

Volumn 180, Issue 12, 2004, Pages 610-613

  Borg, Brigitte M ^a   Reid, David W ^b   Walters, E Haydn ^b   Johns, David P ^b  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; FENOTEROL; FORMOTEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALBUTAMOL; SALMETEROL; TERBUTALINE SULFATE; THEOPHYLLINE;

ARTICLE; ASTHMA; AUSTRALIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION SPACER; INTERMETHOD COMPARISON; LABORATORY TEST; LUNG FUNCTION TEST; MEDICAL SOCIETY; METERED DOSE INHALER; NEW ZEALAND; POSTAL MAIL; PRACTICE GUIDELINE; RESPIRATORY AIRFLOW; SPIROMETRY; TIME;

EID: 3042734364     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb06121.x     Document Type: Article

References (15)

1. National Asthma Council. Asthma management handbook 2002. Melbourne: National Asthma Council Australia Ltd, 2002.
2. Thoracic Society of Australia and New Zealand and The Australian Lung Foundation. The COPDX Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2003. Med J Aust 2003; 178 (6 Suppl): S1-S39.
3. American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am Rev Respir Dis 1991; 144: 1202-1218.
4. European Respiratory Society. Standardized lung function testing. Eur Respir J 1993; 6 (Suppl 16).
5. British Thoracic Society and Association of Respiratory Technicians and Physiologists. Guidelines for the measurement of respiratory function. Respir Med 1994; 88: 165-194.
6. American College of Chest Physicians. Committee report. Criteria for the assessment of reversibility in airways obstruction: report of the committee on emphysema. Chest 1974; 65: 552-553.
7. Morris AH, Kanner RE, Crapo RO, Gardner RM. Clinical pulmonary function testing: a manual of uniform laboratory procedures. 2nd ed. Salt Lake City, Utah: Intermountain Thoracic Society, 1984.
8. British Thoracic Society. Guidelines for the management of COPD. Thorax 1997; 52 (Suppl 5): S1-S28.
9. American Association of Respiratory Care. Clinical practice guideline spirometry, 1996 update. Respir Care 1996; 41: 629-636.
10. Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115: 966-971.
11. Levin DC, Little KS, Laughlin KR, et al. Addition of anticholinergic solution prolongs bronchodilator effect of β agonist in patients with chronic obstructive pulmonary disease. Am J Med 1996; 100: 40S-48S.
12. Riding WD, Dinda P, Chatterjee SS. The bronchodilator and cardiac effects of five pressure-packed aerosols in asthma. Br J Dis Chest 1970; 64: 37-45.
13. Kamburoff PL, Prime FJ. Oral and inhaled salbutamol as a bronchodilator. Br J Dis Chest 1970; 64: 46-54.
14. Blom MW, Sommers DeK. Comparative pharmacology of salmeterol and formeterol and their interaction with salbutamol in healthy volunteers. Clin Drug Invest 1997; 14: 400-404.
15. Seberova E, Andersson A. Oxis (formeterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000; 94: 607-611.